Acadia Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acadia Pharmaceuticals' remlifanserin for the treatment of psychosis associated with Alzheimer's disease. The drug is currently in phase 2 trials for Lewy body dementia with psychosis.
Tickers: $ACAD